Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 878

1.

Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.

Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R.

Int J Oncol. 2003 Jan;22(1):51-7.

PMID:
12469184
2.

p53-dependent radioresistance in ovarian carcinoma cell lines.

Concin N, Zeillinger C, Stimpfel M, Schiebel I, Tong D, Wolff U, Reiner A, Leodolter S, Zeillinger R.

Cancer Lett. 2000 Mar 31;150(2):191-9.

PMID:
10704742
3.

Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression.

Strasser-Wozak EM, Hartmann BL, Geley S, Sgonc R, Böck G, AJ Santos, Hattmannstorfer R, Wolf H, Pavelka M, Kofler R.

Cell Death Differ. 1998 Aug;5(8):687-93.

4.

Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.

Delia D, Goi K, Mizutani S, Yamada T, Aiello A, Fontanella E, Lamorte G, Iwata S, Ishioka C, Krajewski S, Reed JC, Pierotti MA.

Oncogene. 1997 May 8;14(18):2137-47.

5.

G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines.

Bache M, Dunst J, Würl P, Fröde D, Meye A, Schmidt H, Rath FW, Taubert H.

Anticancer Res. 1999 May-Jun;19(3A):1827-32.

PMID:
10470122
6.

Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.

Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.

Gynecol Oncol. 2002 Mar;84(3):404-12.

PMID:
11855878
7.
8.

Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.

Mirjolet JF, Barberi-Heyob M, Didelot C, Peyrat JP, Abecassis J, Millon R, Merlin JL.

Br J Cancer. 2000 Nov;83(10):1380-6.

9.

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.

Cancer Res. 1996 Feb 1;56(3):556-62.

11.

Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.

Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK.

Gynecol Oncol. 2001 Dec;83(3):543-8.

PMID:
11733969
13.
14.

Role of wild type p53 in the G2 phase: regulation of the gamma-irradiation-induced delay and DNA repair.

Schwartz D, Almog N, Peled A, Goldfinger N, Rotter V.

Oncogene. 1997 Nov 20;15(21):2597-607.

15.
17.

Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.

Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.

Cancer Gene Ther. 2000 Nov;7(11):1469-80.

18.

Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells.

Strobel T, Swanson L, Korsmeyer S, Cannistra SA.

Oncogene. 1997 Jun 12;14(23):2753-8.

19.
20.

Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation.

Han Z, Chatterjee D, He DM, Early J, Pantazis P, Wyche JH, Hendrickson EA.

Mol Cell Biol. 1995 Nov;15(11):5849-57.

Supplemental Content

Support Center